• Revenues of $2.7 million, down 1% from 2023
• Net loss of $76.3 million, up 66% from 2023
• Net tangible assets of $1.74 per share as of December 31, 2024

Anteris Technologies Ltd, a medical device company, reported its full year 2024 financial results. Revenues for the year ended December 31, 2024 were $2.7 million, down 1% from $2.7 million in 2023. The company reported a net loss of $76.3 million, up 66% from a net loss of $46.0 million in 2023. The net tangible asset backing per share was $1.74 and $1.04 as of December 31, 2024 and December 31, 2023, respectively. No dividends were proposed, declared, or issued during the year ended December 31, 2024. The consolidated annual financial statements have been audited by KPMG, with the Independent Auditor's opinion including an Emphasis of Matter that the Company has suffered losses from operations that raise substantial doubt about its ability to continue as a going concern. On December 16, 2024, Anteris Technologies Global Corp. (ATGC) received all the issued and outstanding shares of Anteris Technologies Ltd (ATL) pursuant to a scheme of arrangement, with the transaction accounted for as a reverse recapitalization. The prospectus for ATGC's initial public offering included details on the intended use of the net proceeds, primarily for the ongoing development of the DurAVR® THV and preparation for the pivotal trial.

The company intends to use approximately $74.4 million from the IPO proceeds for the ongoing development of DurAVR® THV and the preparation and enrolment of the pivotal trial of DurAVR® THV for treating severe aortic stenosis.